Navigation Links
Lancing tumours into the body

A team of micromachine experts report this week that they have developed tiny spinning screws that could swim along veins, ferrying drugs to infected tissues, or even burrow into tumours to kill them off with a hot lance.Kazushi Ishiyama at Tohoku University in Japan has designed swimming micromachines based on cylindrical magnets.//

Measuring 8 milllimetres long and less than a millimetre in diameter, each magnet is made of a neodymium-iron-boron alloy.Ishiyama made two prototypes to test his idea. The first was designed to move in liquids and had a short section of ceramic pipe attached to each end of the magnet. A wire wound around the pipe’s surface gave it a screw-like thread.

To Test the device, Ishiyama immersed it in a container of silicone oil, which was fixed between two vertical coils of wire. By pumping alternating current through the coils, Ishiyama produced a rotating magnetic field around the container, which set the screw spinning.Because of its threaded surface the screw slowly began to cut through the oil. Its speed increased as the frequency of the rotating magnetic field was ramped up.

Ishiyama’s second prototype, designed to swim and burrow into tissue, used a similar magnet but instead has a pointed, threaded brass tip at one end.This time, Ishiyama tested the device in liquids thicker than oil. He found that it could move at nearly 2 centimetres per second in a thick agar gel. Again, the device moved faster the quicker the magnetic field was rotated, up to a maximum of 20 hertz. Above this frequency, the magnet stopped spinning and ground to a halt.

After the gel tests, Ishiyama decided through real tissue. He found it could screw itself through a 2-centimetre thick chunk of beef steak in 20 seconds. Because the devices are so small, Ishiyama says they could be injected into the body using standard hypodermic needles. Once inside a vein, they could be steered around the body magnetically.Inside the b
'"/>




Page: 1 2

Related medicine news :

1. Multi billion-dollar suit filed against cell phone firm for causing brain tumours
2. Low-radiation treatment for brain tumours
3. Avastin under trial to test efficacy for pancreatic tumours!
4. Awake Surgery to treat Brain tumours
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Lancing tumours into the body

(Date:7/25/2008)... This donation will be used to facilitate...ices for children , Haupp...ivci.com ), a leading integrator of enterprise co...deo conferencing, telepresence, audio visual integ...ed today that it has donated video conferencing eq...
(Date:7/24/2008)...EM, N.C. Researchers at Wake Forest University B...ng clinical belief that the hepatitis C virus slow... itself after HIV patients are treated with a comb...atitis C (HCV) infection is more serious in HIV-in...rding to the Centers for Disease Control. Intraven...
(Date:7/24/2008)...July 24 /PRNewswire-USNewswire/ -- Speaker Nancy P...g in support of the Tom Lantos,and Henry J. Hyde G...nd,Malaria Reauthorization Act of 2008. The bill, ...e this evening by a vote of 303 to 115 and will no...Today the House took an historic vote to pass land...
(Date:7/24/2008)...olo., July 24 /PRNewswire/ -- An Arapahoe County D...ic company what will likely,amount to more than $1...tween the minority shareholders of Inverness-based...-based private company PR Pharmaceuticals, Inc.,Th...dent, Steven Howe, and,CEO, Dr. Patrick Bols, brea...
Breaking Medicine News(10 mins):Health News:Mt. Sinai's Children's Trauma Institute Treatment and Service Adaptation Center Receives Video Conferencing Donation From IVCi 2Health News:Researchers disprove long-standing belief about HIV treatment 2Health News:Researchers disprove long-standing belief about HIV treatment 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2Health News:Jury Award to Englewood Company to Total More Than $1 Million for Breach of Fiduciary Duties in Shareholder Class Action Case 2
... fish at least once a month can minimise the risk ...d researchers. Around 607 participants developed...dy involving more than 43,005 men aged 39 to 76. I...clot that blocks the blood vessel supplying the br...
...ug fluvoxamine has been found by researchers to be...od shifts in women with borderline personality dis...renic, non-bipolar women with borderline// persona...onducted by researchers from various universities ...
...evious research evidence that HRT could reduce ris...n reversed by a recent study of 1000 women of ages...r in the United Kingdom.The aim of the study was t...and progesterone reduced the risk of future heart ...
...chers in there study are trying to observe why su...e but studies are ongoing. It's long been known th...and other mental functions after an operation// - ...function (POCD).Often relatives will say that the ...
Other Medicine News:
(Date:7/22/2008)...July 22 /- Following a,thor...rd of Progen,Pharmaceuticals Limited (ASX: PGL; Na...ed the PI-88 phase 3 study in liver cancer. Progen...existing portfolio of compounds and,the company wi...nd,opportunities through Merger & Acquisition acti...
(Date:7/22/2008)...herapeutics Development Initiative bring MJFF,s,cu...eadline January 20,2009, NEW YORK, July 22 /PRNe...eed delivery of transformative treatments and a cu...ndation for Parkinson,s Research has awarded,$2.7 ...teams. The awards,were granted under MJFF,s Therap...
(Date:7/22/2008)...tudy Confirms Tyrima Exhibits Excellent Drug-Like ...Results Support Initiation of Phase II Clinical Tr...Newswire/ -- CeNeRx BioPharma,Inc., a clinical st...ive,treatments for diseases of the central nervous... candidate Tyrima(TM) into Phase II trials for the...
(Date:7/22/2008)...Calif., July 22 /- Hyperion,Therapeut...tient enrollment,in its Phase 1/2 clinical trial t...avenging effects of HPN-100 (formally called GT4P)...ients with urea cycle disorders,(UCD). The company...quarter,of this year., (Logo: http://www.newscom...
Breaking Medicine Technology:Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Many African Americans have a gene that prolongs life after heart failure 2966 1Many African Americans have a gene that prolongs life after heart failure 2966 2Many African Americans have a gene that prolongs life after heart failure 2966 3Many African Americans have a gene that prolongs life after heart failure 2966 4Allergies Can Dig Into Gardenings Fun 17255 1Allergies Can Dig Into Gardenings Fun 17255 2BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance 4712 1BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance 4712 2BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance 4712 3Angiotechs Corporate Partner Boston Scientific Reports Canadian Approval for TAXUS 28R 29 Liberte 28R 29 Stent System 4710 1Angiotechs Corporate Partner Boston Scientific Reports Canadian Approval for TAXUS 28R 29 Liberte 28R 29 Stent System 4710 2Angiotechs Corporate Partner Boston Scientific Reports Canadian Approval for TAXUS 28R 29 Liberte 28R 29 Stent System 4710 3Angiotechs Corporate Partner Boston Scientific Reports Canadian Approval for TAXUS 28R 29 Liberte 28R 29 Stent System 4710 4
...BRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - AVE...ny focused on the,discovery and development of nov...t it will present a total of 12 oral and poster,pr... Research,(AACR) Annual Meeting on April 14-18, 20...ted to share with the cancer community the,pioneer...
...NDON, April 12, 2007--The costs of eradicating,pol...while high in,the short term, are much lower than ...s without eradication. And a recently developed,mo...ive against,type 1 poliomyelitis than an existing ...rticles published Online and in an upcoming,issue ...
Other Medicine Technology:AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical,Pipeline to Be Featured at AACR 2AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical,Pipeline to Be Featured at AACR 3Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 2Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 3
Stainless Steel
2 Sided Pivoted Closed Ring Design,Pointed And Smooth Sides; in stainless steel.
The e.cam single-detector system offers general purpose scanning flexibility with unrestricted access for gurneys and wheelchairs. This cost-effective system features a clinically versatile open gant
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM
Medicine Products: